Skip to main content
Renal-Cell Carcinoma
CheckMate-9ER: Nivolumab plus Cabozantinib Extends Progression-Free Survival and Overall Survival Compared with Sunitinib
Read More
Renal-Cell Carcinoma
CLEAR: Lenvatinib plus Pembrolizumab Improves Progression-Free Survival and Overall Survival versus Sunitinib in First-Line Setting
Read More
Renal-Cell Carcinoma
KEYNOTE-564: Adjuvant Pembrolizumab Improves Outcomes in RCC
Read More
Ovarian Cancer
How to Sequence Treatment in Relapsed Ovarian Cancer
Read More
Ovarian Cancer
Maintenance Gemogenovatucel-T Immunotherapy in Newly Diagnosed Advanced Ovarian Cancer
Read More
Ovarian Cancer
Patient Self-Reporting of Tolerability in Phase 2 Trial Comparing Gemcitabine plus Adavosertib or Placebo in Women with Platinum-Resistant Epithelial Ovarian Cancer
Read More
Ovarian Cancer
Mirvetuximab Soravtansine plus Bevacizumab in Patients with Recurrent Ovarian Cancer
Read More
Ovarian Cancer
NeoPembrOV Study of Neoadjuvant Chemotherapy with or without Pembrolizumab Followed by Interval Debulking Surgery and Standard Systemic Therapy with or without Pembrolizumab for Advanced High-Grade Serous Carcinoma
Read More
Ovarian Cancer
Optimal Treatment Duration of Bevacizumab plus Carboplatin/Paclitaxel in Advanced Ovarian Cancer
Read More
Ovarian Cancer
Phase 1 Study of GAS6/AXL Inhibitor (AVB-500) in Recurrent, Platinum-Resistant Ovarian Carcinoma
Read More
Page 65 of 196
Results 641 - 650 of 1953